Dr. Carlos E. Vaca, MD
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 236
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
FL license ME67188
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 236
- Services billed
- 2,242
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Telephone medical discussion with physician, 11-20 minutes | 635 | 79 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 276 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 241 | 63 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 193 | 23 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 180 | 22 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 110 | 46 |
| Established patient office or other outpatient visit, 20-29 minutes | 90 | 46 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 47 | 28 |
| Exam of neurobehavioral status, first hour | 30 | 28 |
| Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | 29 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Celecoxib Other prescribers in Miami, FL | 180 |
| Rosuvastatin Calcium Other prescribers in Miami, FL | 173 |
| Diclofenac Sodium Other prescribers in Miami, FL | 158 |
| Ozempic (semaglutide) Other prescribers in Miami, FL | 150 |
| Vitamin D2 (ergocalciferol (vitamin d2)) Other prescribers in Miami, FL | 148 |
| Oxycodone Hcl Other prescribers in Miami, FL | 143 |
| Fluticasone Propionate Other prescribers in Miami, FL | 136 |
| Atorvastatin Calcium Other prescribers in Miami, FL | 134 |
| Amlodipine Besylate Other prescribers in Miami, FL | 125 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Miami, FL | 125 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 11 payments worth $314 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $136 |
|---|---|
| Biotronik Nro, Inc. | $84.24 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.47 |
| GlaxoSmithKline, LLC. | $29.25 |
| Food and Beverage | $314 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $35,990 in research payments for these studies, mostly to the institutions running them.
- Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi US Services Inc. · Recruiting · NCT07190209 - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A phase 3 randomized doubleblind placebocontrolled clinical study evaluating the safety tolerability immunogenicity and efficacy of a variantadapted BNT162B2 vaccine in healthy participants 50 through 64 years of age
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.